Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3 clinical study in primary Sjögren's disease Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39979 VOR BIOPHARMA INC. (Exact Name of Registrant as Specified in its Charter) (State or ot ...

Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunitiesCAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Dallan Murray as Chief Commercial Officer, effective immediately. “We’re thrilled to welcome Dallan to Vor Bio at this important inflection point,” said Jean-Paul Kress, M.D., Chi ...

- New board members bring decades of experience in company building, corporate strategy, commercialization, and business development CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Alexander (Bo) Cumbo and Michel Detheux, Ph.D., to its Board of Directors, effective July 16, 2025. Alexander (Bo) Cumbo currently serves as President and Chief Executive Officer ...

Core Insights - Vor Bio has appointed Dr. Qing Zuraw as Chief Development Officer, bringing over 25 years of experience in clinical development for autoimmune diseases [1][2][4] - Dr. Zuraw previously led the development of telitacicept at RemeGen, achieving multiple regulatory approvals in China for systemic lupus erythematosus, generalized myasthenia gravis, and rheumatoid arthritis [2][3] - Vor Bio aims to advance telitacicept through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions globally [5] Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [5] - The company is working on telitacicept, a novel dual-target fusion protein, to address serious conditions driven by autoantibodies [5] Leadership Experience - Dr. Zuraw has held senior roles at various pharmaceutical companies, including Janssen, Teva, and Biogen, where she led global clinical development programs [4] - She has been instrumental in achieving FDA approvals for therapies in multiple therapeutic areas, showcasing her capability in managing complex clinical trials [4]

Core Insights - Vor Bio has appointed Sandy Mahatme as Chief Financial Officer and Chief Business Officer, effective July 9, 2025, to support the company's transformation and growth in autoimmune disease treatment [1][3] Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, particularly through the development of telitacicept, a novel dual-target fusion protein [5] - The company is advancing telitacicept through Phase 3 clinical development and aims to commercialize it for serious autoantibody-driven conditions worldwide [5] Leadership Experience - Sandy Mahatme brings over 30 years of executive leadership experience in the biopharmaceutical industry, with a strong track record in capital markets, business development, and global operations [2][3] - Prior to joining Vor Bio, Mahatme raised over $2.5 billion in equity and non-dilutive capital at National Resilience, Inc., and led capital formation efforts exceeding $3.5 billion at Sarepta Therapeutics [2][3] Strategic Importance - The appointment of Mahatme is seen as pivotal for Vor Bio as it advances telitacicept through global Phase 3 development and aims to improve the lives of patients with autoimmune diseases [3][5] - Mahatme's experience in navigating strategic growth in both private and public biotech settings is expected to be instrumental for the company's future [3] Inducement Plan - On July 9, 2025, Vor Bio granted Mahatme 13,882,750 restricted stock units (RSUs) as a material inducement to employment, with a vesting schedule over four years [7]

Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [3] - The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization [3] Executive Compensation - The Board of Directors granted CEO Jean-Paul Kress an option to purchase 83,296,638 shares of common stock as an inducement for his employment [1] - The stock option has a ten-year term with an exercise price of $0.89 per share, equal to the closing price on June 26, 2025 [2] - The option will vest over a four-year period, with 25% vesting after 12 months and the remaining shares vesting monthly over the following 36 months [2]

Core Insights - Vor Biopharma Inc. has been upgraded by H.C. Wainwright, marking a significant turnaround for the company following the in-licensing of telitacicept [1][4] - The company has entered into a strategic licensing agreement with RemeGen Co., Ltd. for the development and commercialization of telitacicept outside Greater China [2] Financial Details - Vor Biopharma will pay $125 million upfront, which includes $45 million in cash and $80 million in stock warrants, along with potential milestone payments exceeding $4 billion and tiered royalties [3] - The stock price of Vor Biopharma has increased by 49.1%, reaching $1.58 [7] Market Opportunity - The market potential for telitacicept in generalized myasthenia gravis (gMG) is significant, with an estimated 82,700 people in the U.S. affected in 2021, and 75% of these patients receiving treatment [5] - If priced at $225,000 per patient annually and capturing 15% of the U.S. market, peak annual sales for telitacicept could reach $1.8 billion [5] - Additional sales of $2.7 billion could be generated if the drug successfully launches in the EU and Japan, achieving a 10% market share [6] Management Changes - Jean-Paul Kress has been appointed as CEO and Chairman, replacing Dr. Robert Ang, who will remain as a strategic advisor until October [3]

Core Insights - Vor Bio's shares have surged by 265.5% in the past week, significantly outperforming the industry average increase of 0.8% [1] - The company has entered a licensing agreement with RemeGen to develop and commercialize telitacicept in markets outside of China [1][6] Licensing Agreement Details - The licensing deal is valued at $125 million upfront, which includes $45 million in cash and $80 million in stock warrants, along with potential milestone payments exceeding $4 billion and tiered royalties on future sales [6][7] - Vor Bio will focus on developing telitacicept, a dual-target fusion protein that blocks two proteins, BAFF and APRIL, to treat autoimmune diseases [2][7] Clinical Development - A global phase III study for telitacicept in treating generalized myasthenia gravis (gMG) is currently ongoing in the United States, Europe, and South America, with initial data expected in the first half of 2027 [3] Leadership Changes - Vor Bio has appointed Jean-Paul Kress as the new CEO and chairman, following the resignation of the previous CEO, Robert Ang [3][6] Company Outlook - The licensing agreement is seen as a pivotal move that may prevent Vor Bio from shutting down its operations, which was previously announced due to financial difficulties [8]

Core Viewpoint - Rongchang Biopharmaceutical's significant licensing agreement with Vor Bio, valued at up to $4.23 billion, led to an unexpected 18.36% drop in its stock price, raising concerns about the market's perception of the deal [2]. Group 1: Licensing Agreement Details - On June 25, Rongchang Biopharmaceutical announced a licensing agreement with Vor Bio, granting exclusive rights to develop and commercialize the drug Tai Tasi Pi outside of Greater China [2]. - The agreement includes an upfront payment of $125 million, which consists of a $45 million initial payment and $80 million in warrants, along with potential milestone payments of up to $4.1 billion and sales royalties in the high single to double-digit percentage range [2]. Group 2: Product and Financial Performance - Tai Tasi Pi, Rongchang's core innovative drug, received conditional approval in March 2021 and is currently approved for indications such as myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis [3]. - In 2024, Rongchang's revenue reached 1.717 billion yuan, a year-on-year increase of 58.54%, although it reported a net loss of 1.468 billion yuan [4]. - The significant revenue growth is attributed to increased sales of Tai Tasi Pi and another product, with R&D expenses amounting to 1.54 billion yuan, representing 89.69% of total revenue [4]. Group 3: Vor Bio Company Concerns - Vor Bio has not generated any revenue since its inception and reported net losses of $118 million and $117 million for 2023 and 2024, respectively, with a cumulative deficit of $457 million as of December 31, 2024 [5]. - The company announced significant layoffs, planning to cut 147 full-time employees, approximately 95% of its workforce, and to gradually shut down its clinical and manufacturing operations [5]. - Vor Bio also experienced major management changes, including the departure of its CFO, Chief Scientific Officer, and head of technical operations [6].